Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Basit Öğe Kaydı
dc.authoridÇınarka, Halit/0000-0002-4910-149X
dc.authoridOksuz, Ergun/0000-0002-5723-5965
dc.authoridCansever, Levent/0000-0003-4928-1790
dc.authorwosidÖzet, ahmet/ABC-9831-2021
dc.authorwosidÇınarka, Halit/AAK-6830-2021
dc.authorwosidYılmaz, Ülkü/HKN-2974-2023
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidOksuz, Ergun/K-8238-2012
dc.authorwosidCansever, Levent/HLX-4971-2023
dc.contributor.authorCicin, Irfan
dc.contributor.authorOksuz, Ergun
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorMalhan, Simten
dc.contributor.authorGumus, Mahmut
dc.contributor.authorYilmaz, Ulku
dc.contributor.authorCansever, Levent
dc.date.accessioned2024-06-12T11:07:54Z
dc.date.available2024-06-12T11:07:54Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. Results Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be euro8772), for non-small-cell lung cancer to be euro10,167. Total annual direct medical cost was euro497.9 million, total annual indirect medical cost was euro1.1 billion and total economic burden of lung cancer was euro1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Conclusions Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments.en_US
dc.description.sponsorshipTurkish Society of Lung Cancer; AstraZeneca Turkey; Lung Health and Intensive Care Association; University of Health Sciences; Turkish Society of Medical Oncology; National Cancer Institute; Turkish Respiratory Societyen_US
dc.description.sponsorshipThis study was supported by Turkish Society of Lung Cancer, Lung Health and Intensive Care Association, University of Health Sciences, Turkish Society of Medical Oncology, National Cancer Institute and Turkish Respiratory Society. The creation of the model used in this study, statistics and editorial support were sponsored by AstraZeneca Turkey in the context of unconditional scientific support. AstraZeneca Turkey has not contributed to the content of the study.en_US
dc.identifier.doi10.1186/s13561-021-00322-2
dc.identifier.issn2191-1991
dc.identifier.issue1en_US
dc.identifier.pmid34173876en_US
dc.identifier.scopus2-s2.0-85109033970en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1186/s13561-021-00322-2
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22227
dc.identifier.volume11en_US
dc.identifier.wosWOS:000666853400001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofHealth Economics Reviewen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLung Canceren_US
dc.subjectPractice Patternsen_US
dc.subjectCost Of Illnessen_US
dc.subjectDirect Costsen_US
dc.subjectIndirect Costsen_US
dc.subjectEconomic Burdenen_US
dc.subjectTurkeyen_US
dc.subjectSmall-Cellen_US
dc.subjectTreatment Patternsen_US
dc.subjectLost Productivityen_US
dc.subjectMortalityen_US
dc.subjectCareen_US
dc.subjectManagementen_US
dc.subjectCaregiversen_US
dc.subjectTherapyen_US
dc.subjectEuropeen_US
dc.subjectStageen_US
dc.titleEconomic burden of lung cancer in Turkey: a cost of illness study from payer perspectiveen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu